The enormous health and economic impacts of epidemics and pandemics has become one of the defining public policy and health issues in Europe and throughout the world. A new urgency is required to understand, rapidly respond to, and vaccinate against viruses with epidemic and pandemic potential. The major challenge for the modern vaccines is the induction of long-term protective immunity, as clearly demonstrated by fast waning of protection for current COVID-19 vaccines. VICI-DISEASE is an ambitious project which combines existing cutting-edge expertise in a tried and tested consortium, with new advances in this critical field. The consortium’s main objective is to develop a vaccine candidate portfolio and perform a clinical proof-of-concept study, to enable stocks of vaccine candidates ready for further development (Phase 2&3) in case of pandemic outbreaks. The primary candidate will be Nipah virus (NiV), a high-mortality viral disease with no vaccines or treatments. Our vaccine is based on NiV G protein displayed on capsid Virus Like Particle (cVLP), enabled by adapting template processes from our recent COVID-19 vaccine (currently in Phase 3), and expected to provide best-in-class longevity as shown for COVID-19. The VICI-DISEASE consortium’s objective is to develop and perform a clinical proof-of-concept study for • a highly effective (>90% protection), • long-term protective (>2 years), • NiV virus cVLP vaccine, • by adapting template processes established for our COVID-19 vaccine (currently in Phase 3), • within 48 months in a Phase 1/2a clinical study, • to help protect medical workers and the public from future NiV and Hendra virus outbreaks, • and establish a pipeline of novel filovirus vaccines through pre-clinical proof-of-concept studies. We address the call topic by improving pandemic preparedness and response through development of a NiV vaccine to Ph1/2 and two filovirus vaccines to pre-clinical proof-of-concept.